Plant · Scientific monograph
Linum usitatissimum
Flax / Linseed
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Gastrointestinal Research, Blood Pressure Mechanisms
Research overview
Historical use
Linseed has long been used as a bulk-forming laxative; EMA distinguishes well-established use of seed for habitual constipation from traditional demulcent use for mild gastrointestinal discomfort [5].
Modern research context
Flaxseed products have been studied for bowel function and blood-pressure outcomes, with seed, oil and lignan extracts representing different interventions [1][2][5]. A 2023 meta-analysis of 33 trials (2427 participants) reported modest pooled blood-pressure reductions but very high heterogeneity (I² above 92%); the archive uses conservative Level B for the studied pressure outcomes rather than generalizing to every product [1]. An earlier analysis also found formulation-dependent results [2]. EMA recognizes seed as a bulk laxative, while demulcent use is traditional (Level T); regulatory well-established use is not itself an archive Level A clinical-trial score [5]. A separate triple-blind trial studied flaxseed regimens for 12 weeks, but its abstract gives inconsistent participant totals, so it is not used for a precise sample-size or effect claim [4].
Adverse effects
EMA lists flatulence as common and hypersensitivity including anaphylaxis-like reactions as very rare. Insufficient fluid can cause choking, oesophageal blockage or intestinal obstruction; excessive seed exposure can cause abdominal discomfort and flatulence [5]. NCCIH also notes bloating, fullness and diarrhea with higher exposures [6].
Contraindications
EMA contraindicates hypersensitivity, swallowing/throat disorders, intestinal narrowing or obstruction/ileus, megacolon and certain unexplained bowel symptoms, including rectal bleeding or persistent sudden bowel-habit changes. Medicinal use under age 12 is not recommended; EMA also cautions against use in women with hormone-dependent tumours [5]. A validated perioperative washout interval was not identified.
Clinical and phytochemical data
Used part
Dried ripe seeds, whole/broken or milled, and seed mucilage. Seed oil lacks the same bulk-forming fibre exposure; purified lignan extracts have a separate pharmacokinetic and safety evidence base [3][5][6].
Primary active compounds
Mucilage polysaccharides and dietary fibre [5]
Secoisolariciresinol diglycoside (SDG; lignan) [3]
Alpha-linolenic acid in seed oil [6]
Mechanism of action
For bowel effects, water-binding mucilage increases intestinal content volume and softens stool, with stretch-related effects on transit; this is a local bulk mechanism described by EMA, not a receptor-specific systemic action [5]. Blood-pressure mechanisms are not conclusively assigned to a single constituent in the human meta-analyses [1][2].
Pharmacokinetics
Absorption
In healthy postmenopausal women given purified flax lignan extracts, secoisolariciresinol peaked at approximately 5–7 hours; enterodiol and enterolactone appeared later. These results describe SDG-derived compounds, not whole-seed mucilage or seed oil [3].
Distribution
Human tissue distribution of complete seed products was not established in the selected sources; purified-lignan serum exposure does not establish all tissue concentrations [3].
Metabolism
SDG is hydrolyzed to secoisolariciresinol and converted by intestinal bacteria to enterodiol and enterolactone [3]. Some seed bulk material is fermented to short-chain fatty acids while some is passed in stool [5].
Excretion
Human SDG studies measured urinary lignans and reported approximate serum half-lives of 4.8 hours for secoisolariciresinol, 9.4 hours for enterodiol and 13.2 hours for enterolactone; these cannot define whole-seed clearance or impairment dosing [3].
Safety and interactions
Drug interactions
EMA warns that linseed can delay intestinal absorption of medicines and specifies separation of at least half to one hour. Co-use with motility-suppressing medicines such as opioids or loperamide requires medical supervision because of obstruction risk [5]. NCCIH describes anticoagulant/antiplatelet interactions as theoretical, not established clinical bleeding interactions [6].
Toxicity
NCCIH advises against eating raw or unripe seeds because of potentially toxic constituents; seed preparation matters [6]. EMA identifies obstruction risk when fluid intake is inadequate and incomplete reproductive/genotoxicity/carcinogenicity testing. No universal long-term toxicity threshold can be inferred from short supplementation trials [5][6].
Special precautions
Pregnancy
Medicinal pregnancy safety is not established and EMA does not recommend use; NCCIH notes inconclusive possible pregnancy risk. This does not equate medicinal preparations with ordinary food exposure [5][6].
Lactation
Milk transfer and infant safety are insufficiently characterized; EMA does not recommend medicinal use while breastfeeding [5][6].
Hepatic impairment
No validated hepatic-impairment adjustment for medicinal seed or lignan extract was established in the selected sources [3][5].
Renal impairment
No validated renal-impairment adjustment is established. Fluid-dependent bulk use requires individual assessment when fluid intake is restricted; this is a precaution rather than a tested dosing rule [5].
Sources and references
- [1] - Li L, Li H, Gao Y, Vafaei S, Zhang X, Yang M. Effect of flaxseed supplementation on blood pressure: a systematic review, and dose-response meta-analysis of randomized clinical trials. Food & function, 2023. PMID: 36622248. DOI: 10.1039/d2fo02566c
- [2] - Ursoniu S, Sahebkar A, Andrica F, Serban C, Banach M, Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Effects of flaxseed supplements on blood pressure: A systematic review and meta-analysis of controlled clinical trial. Clinical nutrition (Edinburgh, Scotland), 2016. PMID: 26071633. DOI: 10.1016/j.clnu.2015.05.012
- [3] - Setchell KD, Brown NM, Zimmer-Nechemias L, Wolfe B, Jha P, Heubi JE. Metabolism of secoisolariciresinol-diglycoside the dietary precursor to the intestinally derived lignan enterolactone in humans. Food & function, 2014. PMID: 24429845. DOI: 10.1039/c3fo60402k
- [4] - Toulabi T, Yarahmadi M, Goudarzi F, Ebrahimzadeh F, Momenizadeh A, Yarahmadi S. Effects of flaxseed on blood pressure, body mass index, and total cholesterol in hypertensive patients: A randomized clinical trial. Explore (New York, N.Y.), 2022. PMID: 34119421. DOI: 10.1016/j.explore.2021.05.003
- [5] - EMA/HMPC. European Union herbal monograph on Linum usitatissimum L., semen. 10 March 2015. https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
- [6] - NCCIH. Flaxseed and Flaxseed Oil. Accessed 25 October 2026. https://www.nccih.nih.gov/health/flaxseed-and-flaxseed-oil